Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma

Kudoh, Kazuya; Kikuchi, Yoshihiro; Kita, Toru; Tode, Takehiko; Takano, Masashi; Hirata, Junko; Mano, Yoshinori; Yamamoto, Kenji; Nagata, Ichiro

doi:10.1159/000010062

Cited by 50 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we found 40% of ovarian mucinous carcinomas to be associated with an elevated serum CA19.9 level. This is at variance with other studies that have reported an elevated CA19.9 level in between 76.9% and 83.3% of ovarian mucinous carcinomas 5 13. These latter studies included larger numbers of mucinous carcinoma than our study.…”

Section: Discussioncontrasting

confidence: 99%

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

et al. 2010

View full text Add to dashboard Cite

AimsCA19.9 is a monosialoganglioside secreted by mucinous tumours of the gastrointestinal tract, including the pancreas and biliary tree. Limited studies have shown that this tumour marker may also be elevated in primary ovarian mucinous neoplasms, but no study has assessed whether serum CA19.9 levels can be used to predict if a primary ovarian mucinous tumour is benign, borderline or malignant. The aim of this study was to correlate the serum CA19.9 level with the histological features in a large series of primary ovarian mucinous neoplasms.Methods144 cases of primary ovarian mucinous neoplasm (79 benign, 45 borderline and 20 malignant) were identified in which a preoperative serum CA19.9 level had been performed. The association between the serum levels and the histological subtype and a variety of other parameters was investigated. In a subset of cases, immunohistochemical staining for CA19.9 was performed on tumour blocks.ResultsSerum CA19.9 levels were elevated in 27%, 38% and 40% of mucinous cystadenomas, borderline mucinous tumours and mucinous carcinomas, respectively. Markedly elevated levels of serum CA19.9 were observed in each group, with the highest serum CA19.9 measurements being noted in borderline mucinous tumours. There was no relationship between the serum CA19.9 level and whether the tumours were benign, borderline or malignant (Kruskal–Wallis test p value=0.32). A weak but statistically significant correlation was found between tumour maximum dimension and CA19.9 level (Spearman's rank correlation coefficient=0.17, p=0.04). In those cases in which CA19.9 immunohistochemistry was performed, all tumours showed positive staining for CA19.9, with 60% of these cases being associated with an elevated serum CA19.9 level.ConclusionPreoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant. Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.

show abstract

Section: Discussioncontrasting

confidence: 99%

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, in the current study the serum STN level was not a prognostic factor for the survival of colorectal cancer patients after surgery. We are not aware of any report that has described the prognostic value of preoperative serum STN levels in colorectal cancer patients, although the prognostic value for patients with gastric cancer and ovarian cancer has been reported [40][41][42]. The incidence of high serum STN levels in the colorectal cancer patients in the present study was lower than that in patients with gastric (13-28%) or ovarian cancer (50.0-63.2%) [40][41][42].…”

Section: Discussioncontrasting

confidence: 60%

“…We are not aware of any report that has described the prognostic value of preoperative serum STN levels in colorectal cancer patients, although the prognostic value for patients with gastric cancer and ovarian cancer has been reported [40][41][42]. The incidence of high serum STN levels in the colorectal cancer patients in the present study was lower than that in patients with gastric (13-28%) or ovarian cancer (50.0-63.2%) [40][41][42]. Therefore, serum STN levels need to be determined in a larger number of colorectal cancer patients to clarify the prognostic value of this carbohydrate antigen.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Serum Sialyl Lewis<sup>a</sup>, Sialyl Lewis<sup>x</sup> and Sialyl Tn Antigens in Blood from the Tumor Drainage Vein of Colorectal Cancer Patients

Nakagoe¹,

Sawai²,

Tsuji³

et al. 2001

Tumor Biol

View full text Add to dashboard Cite

The serum levels of sialyl Lewis^a (CA19-9), sialyl Lewis^x (SLX), sialyl Tn (STN) and carcinoembryonic antigen (CEA) in peripheral venous blood and tumor drainage venous blood of colorectal cancer patients were examined to determine their value as prognostic factors after surgery. Blood samples were obtained from the peripheral vein and from the tumor drainage vein from 124 colorectal cancer patients during surgical excision of the tumor. The patients were divided into high-antigen and low-antigen groups for each antigen in each location. Serum levels of SLX, STN and CEA in tumor drainage venous blood (d-SLX, d-STN and d-CEA, respectively) were significantly higher than in peripheral venous blood (p-SLX, p-STN and p-CEA, respectively). The survival time after surgery for patients with high d-SLX or d-CEA levels and low levels of the same antigen in peripheral venous blood was significantly shorter than the survival time for those patients with low levels of antigen at both sites (p = 0.0003 or p = 0.0406, respectively). Cox’s regression analysis revealed that a high d-SLX or high d-CEA level was an independent prognostic variable for patient survival. In conclusion, determining d-SLX or d-CEA is more useful than p-SLX or p-CEA in predicting the outcome for colorectal cancer patients.

show abstract

“…Some authors found that serum concentrations of TPA correlated with length of survival in lung, prostate, colorectal, and bladder cancer [21,[35][36][37]. However, other authors observed that elevated serum concentrations of TPA were not associated with a worse prognosis in colorectal, ovarian, endometrial, and cervical cancer [24,[38][39][40]. Overall, the prognostic value of serum concentrations of TPA has been discussed controversially.…”

Section: Discussionmentioning

confidence: 99%

Serum Concentrations of Tissue Polypeptide Antigen in Patients with Vulvar Intraepithelial Neoplasia and Vulvar Cancer

Hefler

Tempfer²,

Frischmuth³

et al. 2000

Tumor Biol

View full text Add to dashboard Cite

The aim of the present study was to evaluate the clinical usefulness of the cytokeratin tumor marker tissue polypeptide antigen (TPA) in patients with vulvar cancer. This retrospective study comprises 41 patients with vulvar cancer FIGO stages I–III, 17 patients with vulvar intraepithelial neoplasia (VIN) III, and 40 healthy female controls. Serum concentrations of TPA were measured using a microparticle enzyme immunoassay. Results were correlated to clinical data. Median serum concentrations of TPA in healthy female controls, patients with VIN III, and patients with vulvar cancer were 42 U/l (range 12–192), 53 U/l (range 17–127.9) and 57 U/l (range 4.2–423), respectively (Mann-Whitney U test, p = 0.8). Serum concentrations of TPA were not associated with stage of disease, histological grade, and age at the time of diagnosis. In vulvar cancer patients, elevated serum concentrations of TPA prior to therapy were not associated with a shortened disease-free or overall survival (log-rank test: p = 0.5 and p = 0.9, respectively). In a multivariate Cox regression model comprising tumor stage and TPA, tumor stage, but not TPA revealed a statistically significant influence on disease-free (Cox proportional hazard regression model, p = 0.05 and p = 0.6, respectively) and overall (Cox proportional hazard regression model, p = 0.04 and p = 0.8, respectively) survival of patients with vulvar cancer. We conclude that cytokeratin expression, as reflected by serum concentrations of TPA, does not play a role in the natural history of vulvar cancer. The evaluation of serum concentrations of TPA prior to therapy is not recommended.

show abstract

Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma

Cited by 50 publications

References 9 publications

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

Prognostic Value of Serum Sialyl Lewis<sup>a</sup>, Sialyl Lewis<sup>x</sup> and Sialyl Tn Antigens in Blood from the Tumor Drainage Vein of Colorectal Cancer Patients

Serum Concentrations of Tissue Polypeptide Antigen in Patients with Vulvar Intraepithelial Neoplasia and Vulvar Cancer

Contact Info

Product

Resources

About